GH Research PLC (GHRS): Price and Financial Metrics
GHRS Price/Volume Stats
| Current price | $6.85 | 52-week high | $14.99 |
| Prev. close | $7.39 | 52-week low | $5.08 |
| Day low | $6.72 | Volume | 76,700 |
| Day high | $7.63 | Avg. volume | 78,084 |
| 50-day MA | $8.38 | Dividend yield | N/A |
| 200-day MA | $10.19 | Market Cap | 356.39M |
GHRS Stock Price Chart Interactive Chart >
GH Research PLC (GHRS) Company Bio
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
GHRS Price Returns
| 1-mo | -28.79% |
| 3-mo | -7.18% |
| 6-mo | -42.19% |
| 1-year | 24.77% |
| 3-year | -71.65% |
| 5-year | N/A |
| YTD | 18.10% |
| 2023 | -40.33% |
| 2022 | -58.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...